BR112019005247A2 - terapia para o câncer resistente a fármacos por meio de administração de conjugado de anticorpo anti-her2/fármaco - Google Patents
terapia para o câncer resistente a fármacos por meio de administração de conjugado de anticorpo anti-her2/fármacoInfo
- Publication number
- BR112019005247A2 BR112019005247A2 BR112019005247A BR112019005247A BR112019005247A2 BR 112019005247 A2 BR112019005247 A2 BR 112019005247A2 BR 112019005247 A BR112019005247 A BR 112019005247A BR 112019005247 A BR112019005247 A BR 112019005247A BR 112019005247 A2 BR112019005247 A2 BR 112019005247A2
- Authority
- BR
- Brazil
- Prior art keywords
- drug
- cancer therapy
- her2 antibody
- resistant cancer
- administering anti
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 4
- 229940079593 drug Drugs 0.000 title abstract 3
- 238000011275 oncology therapy Methods 0.000 title 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 title 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940043275 anti-HER2 drug Drugs 0.000 abstract 1
- 239000000611 antibody drug conjugate Substances 0.000 abstract 1
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
como um tratamento eficaz para um câncer que expressa her2 que tem resistência ou refratariedade a um fármaco anti-her2 existente, é fornecido um agente terapêutico e um método de tratamento que usa um conjugado de anticorpo-fármaco, em que um ligante e um fármaco representado pela fórmula: -(succinimid-3-il-n)-ch2ch2ch2ch2ch2-c(=o)-ggfg-nh-ch2-o-ch2-c(=o)-(nh-dx) são conjugados a um anticorpo anti-her2.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016199341 | 2016-10-07 | ||
JP2017097589 | 2017-05-16 | ||
JP2017172814 | 2017-09-08 | ||
PCT/JP2017/036215 WO2018066626A1 (ja) | 2016-10-07 | 2017-10-05 | 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019005247A2 true BR112019005247A2 (pt) | 2019-06-04 |
Family
ID=61831486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019005247A BR112019005247A2 (pt) | 2016-10-07 | 2017-10-05 | terapia para o câncer resistente a fármacos por meio de administração de conjugado de anticorpo anti-her2/fármaco |
Country Status (11)
Country | Link |
---|---|
US (1) | US20190330368A1 (pt) |
EP (1) | EP3524267A4 (pt) |
JP (3) | JPWO2018066626A1 (pt) |
KR (2) | KR20190066026A (pt) |
CN (1) | CN109789211A (pt) |
AU (1) | AU2017341000A1 (pt) |
BR (1) | BR112019005247A2 (pt) |
CA (1) | CA3036941C (pt) |
SG (1) | SG10201912173RA (pt) |
TW (2) | TW202245846A (pt) |
WO (1) | WO2018066626A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3673918A4 (en) * | 2017-08-23 | 2021-05-19 | Daiichi Sankyo Company, Limited | ANTIBODY-DRUG CONJUGATE PREPARATION AND ASSOCIATED LYOPHILIZATION |
US20190194348A1 (en) * | 2017-11-10 | 2019-06-27 | Oregon Health & Science University | Treatment of therapy-resistant her-2 positive breast cancer |
KR20210014660A (ko) | 2018-05-28 | 2021-02-09 | 다이이찌 산쿄 가부시키가이샤 | 항 her2 항체-약물 콘쥬게이트 투여에 의한 her2 변이암의 치료 |
BR112021001194A2 (pt) * | 2018-07-25 | 2021-04-27 | Daiichi Sankyo Company, Limited | métodos para produzir um conjugado anticorpo-fármaco e para produzir uma composição farmacêutica |
WO2020027100A1 (ja) | 2018-07-31 | 2020-02-06 | 第一三共株式会社 | 抗体-薬物コンジュゲート投与による転移性脳腫瘍の治療 |
JP7254818B2 (ja) * | 2018-09-06 | 2023-04-10 | 第一三共株式会社 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
US20200306243A1 (en) | 2019-03-29 | 2020-10-01 | Medimmune Limited | Compounds and conjugates thereof |
KR20220115566A (ko) | 2019-11-15 | 2022-08-17 | 시아겐 인크. | 항-her2 항체-약물 접합체와 조합된 투카티닙으로 her2 양성 유방암을 치료하는 방법 |
CA3168882A1 (en) | 2020-02-25 | 2021-09-02 | Mediboston, Inc. | Camptothecin derivatives and conjugates thereof |
TW202216214A (zh) | 2020-07-20 | 2022-05-01 | 日商第一三共股份有限公司 | 抗her2抗體-藥物結合物與her二聚化抑制劑的組合 |
KR20230079085A (ko) | 2020-09-30 | 2023-06-05 | 듀얼리티 바이올로직스 (쑤저우) 컴퍼니 리미티드 | 항종양 화합물 및 그의 제조 방법 및 용도 |
KR102247908B1 (ko) * | 2020-10-08 | 2021-05-06 | 주식회사 엠디엡투스 | Her2 압타머-항암 약물 복합체 및 이의 용도 |
WO2022099762A1 (zh) * | 2020-11-12 | 2022-05-19 | 博瑞生物医药(苏州)股份有限公司 | 一种抗体偶联物中间体及其制备方法 |
US20220378929A1 (en) * | 2021-02-25 | 2022-12-01 | MediBoston Limted | Anti-her2 antibody-drug conjugates and uses thereof |
CN117750980A (zh) * | 2021-05-24 | 2024-03-22 | 荣昌生物制药(烟台)股份有限公司 | Her2靶向抗体-药物偶联物用于治疗her2低表达乳腺癌的用途 |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
CN116789733A (zh) * | 2022-07-05 | 2023-09-22 | 上海药明合联生物技术有限公司 | 偶联连接子 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
JPH06508511A (ja) | 1990-07-10 | 1994-09-29 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的な結合ペアーの構成員の製造方法 |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JP3008226B2 (ja) | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Technology Ltd., Melbourn | Methoden zur Herstellung humanisierter Antikörper |
ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
DE69333823T2 (de) | 1992-03-24 | 2006-05-04 | Cambridge Antibody Technology Ltd., Melbourn | Verfahren zur herstellung von gliedern von spezifischen bindungspaaren |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
JPH08337584A (ja) | 1995-04-10 | 1996-12-24 | Dai Ichi Seiyaku Co Ltd | 縮合六環式アミノ化合物、これを含有する医薬及びその製法 |
TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
ES2340112T3 (es) | 1998-04-20 | 2010-05-28 | Glycart Biotechnology Ag | Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos. |
AU765409B2 (en) | 1998-10-30 | 2003-09-18 | Daiichi Pharmaceutical Co., Ltd. | DDS compounds and method for assaying the same |
CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Hakko Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
DE10084743T1 (de) | 1999-06-25 | 2002-08-14 | Genentech Inc | Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern |
WO2001000244A2 (en) | 1999-06-25 | 2001-01-04 | Genentech, Inc. | METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES |
EP1331266B1 (en) | 2000-10-06 | 2017-01-04 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
RS62618B1 (sr) * | 2014-01-31 | 2021-12-31 | Daiichi Sankyo Co Ltd | Anti-her2 antitelo-lek konjugat |
-
2017
- 2017-10-05 CN CN201780062054.2A patent/CN109789211A/zh active Pending
- 2017-10-05 CA CA3036941A patent/CA3036941C/en active Active
- 2017-10-05 BR BR112019005247A patent/BR112019005247A2/pt unknown
- 2017-10-05 US US16/334,008 patent/US20190330368A1/en active Pending
- 2017-10-05 SG SG10201912173RA patent/SG10201912173RA/en unknown
- 2017-10-05 EP EP17858462.9A patent/EP3524267A4/en active Pending
- 2017-10-05 AU AU2017341000A patent/AU2017341000A1/en active Pending
- 2017-10-05 KR KR1020197011914A patent/KR20190066026A/ko not_active IP Right Cessation
- 2017-10-05 KR KR1020237038566A patent/KR20230158641A/ko active Search and Examination
- 2017-10-05 WO PCT/JP2017/036215 patent/WO2018066626A1/ja active Application Filing
- 2017-10-05 JP JP2018543951A patent/JPWO2018066626A1/ja active Pending
- 2017-10-06 TW TW111125911A patent/TW202245846A/zh unknown
- 2017-10-06 TW TW106134472A patent/TWI827534B/zh active
-
2022
- 2022-04-15 JP JP2022067540A patent/JP2022095908A/ja active Pending
-
2024
- 2024-02-07 JP JP2024016749A patent/JP2024054226A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022095908A (ja) | 2022-06-28 |
JPWO2018066626A1 (ja) | 2019-07-18 |
JP2024054226A (ja) | 2024-04-16 |
CA3036941C (en) | 2023-02-21 |
US20190330368A1 (en) | 2019-10-31 |
CA3036941A1 (en) | 2018-04-12 |
KR20230158641A (ko) | 2023-11-20 |
AU2017341000A1 (en) | 2019-04-11 |
WO2018066626A1 (ja) | 2018-04-12 |
SG10201912173RA (en) | 2020-02-27 |
CN109789211A (zh) | 2019-05-21 |
KR20190066026A (ko) | 2019-06-12 |
TWI827534B (zh) | 2024-01-01 |
TW202245846A (zh) | 2022-12-01 |
EP3524267A1 (en) | 2019-08-14 |
TW201818973A (zh) | 2018-06-01 |
EP3524267A4 (en) | 2020-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019005247A2 (pt) | terapia para o câncer resistente a fármacos por meio de administração de conjugado de anticorpo anti-her2/fármaco | |
PH12019502545A1 (en) | Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate | |
BR112018073574A2 (pt) | conjugados de anticorpo-fármaco anti-cmet e métodos para a sua utilização | |
BR112018006016A2 (pt) | intermediário de ligante-droga, compostos conjugados de anticorpo-droga, composições farmacêuticas, métodos para tratar câncer, método de produção de um composto conjugado e conjugado de anticorpo-droga | |
BR112016024363A2 (pt) | conjugado de anticorpo-fármaco e seu uso para tratamento de câncer | |
PE20150091A1 (es) | Anticuerpos anti-sez6 y metodos de empleo | |
PE20150090A1 (es) | Moduladores y metodos de empleo novedosos referencia cruzada a solicitudes | |
CY1124651T1 (el) | Αντισωμα εναντι toy her2 και συζευγμα αυτου | |
WO2017031458A3 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
CL2015003343A1 (es) | Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico. | |
EA201790674A1 (ru) | Индуцирующий цитотоксичность терапевтический агент | |
WO2014134483A3 (en) | Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents | |
BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
BR112016027048A8 (pt) | uso de um composto de fórmula i no tratamento de câncer cerebral e glioblastoma multiforme mgmt positivo | |
MX361218B (es) | Análogos de spliceostatina. | |
MX2019012464A (es) | Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl. | |
WO2015118030A3 (en) | Antibody-drug conjugates and immunotoxins | |
UY36075A (es) | Derivados de tubulisina | |
EA201791203A1 (ru) | ЛЕКАРСТВЕННЫЙ КОНЪЮГАТ АНТИТЕЛА ПРОТИВ с-МЕТ | |
WO2015118031A3 (en) | Antibody-drug conjugates and immunotoxins | |
WO2015164392A8 (en) | Novel anti-rnf43 antibodies and methods of use | |
BR112016024619A2 (pt) | conjugado de anticorpo ao igf-1r-fármaco e seu uso para o tratamento de câncer | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
CA2908742C (en) | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer | |
BR112021017616A2 (pt) | Conjugado de derivado de anticorpo anti-her2-pirrolobenzodiazepina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122022026513-8 PROTOCOLO 870220121587 EM 23/12/2022 15:06. |